GeneDx is trading 6.74% higher at $90.94, with the advance appearing primarily sector-driven. - Shares rebounded from a September 23 close of $85.20. - No verified company-specific announcement, earnings update, regulatory action, or analyst change was identified for September 24, 2026. The September 9 Beren Therapeutics collaboration does not directly explain the move. - Biotechnology ETF XBI was down 2.04% in the broader session, with markets pressured by elevated yields and oil prices.